No role for the CYP3A53 polymorphism in intestinal and hepatic metabolism of midazolam

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 2008-10, Vol.64 (10), p.1033-1035
Main Authors: Tomalik-Scharte, D., Doroshyenko, O., Kirchheiner, J., Jetter, A., Lazar, A., Klaassen, T., Frank, D., Wyen, C., Fätkenheuer, G., Fuhr, U.
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Biological Availability
Biomedical and Life Sciences
Biomedicine
Case-Control Studies
Cytochrome P-450 CYP3A - genetics
Cytochrome P-450 CYP3A - metabolism
Female
HIV Infections - blood
HIV Seropositivity - blood
Humans
Injections, Intravenous
Intestines - metabolism
Letter to the Editors
Liver - metabolism
Male
Metabolic Clearance Rate
Midazolam - administration & dosage
Midazolam - blood
Midazolam - metabolism
Midazolam - pharmacokinetics
Middle Aged
Pharmacology/Toxicology
Polymorphism, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0031-6970
1432-1041
DOI:10.1007/s00228-008-0503-9